Newsroom - Glenmark Pharmaceuticals

Skip to content

IGI
GLOBAL PRESENCE
- US
- INDIA
- EUROPE
- LATIN AMERICA
- ROW
  - ASIA
    - MALAYSIA
  - AUSTRALIA
  - ME & Africa
  - RUSSIA & CIS
CONTACT US
FOLLOW US

ABOUT US
- ABOUT US
  
  ABOUT US
  
  Evolution
  
  The achievements that highlight our journey
  
  Executive Team
  
  The team who translates vision into reality
  
  Governance
  
  The tenets of our functioning
  
  Awards
  
  Striving for Excellence
  
  Board of Directors
  
  The people who pave the way for a new world
INNOVATION
- Our Innovation
  
  INNOVATION
  
  Our Innovation Journey
  
  Centres of Innovation
  
  Pipeline
PRODUCTS
- Products
  PRODUCTS
  
  Overview
  
  Therapy Areas
  
  Global Presence +
  
  – USA
  – India
  – Europe
  – Latin America
  – Row
  * Asia
  * Africa
  * Russia and CIS
  
  Quality at Glenmark
  
  Manufacturing Facilities
  
  Business Development
RESPONSIBILITY
- Responsibility
  RESPONSIBILITY
  
  Our Communities
  
  Enriching lives for a healthier and
  happier world
  
  Child Health
  
  Access to Health Care
  
  Promotion of Sports
  
  Sustainable Livelihoods
  
  Glenmark Joy of Giving
  
  Water Conservation and Mgmt
  
  Impact Accessment Reports
  
  Support during Covid-19
  
  Our Planet
  
  Operating responsibly towards a greener
  planet
  
  Our Policy
  
  Our Commitment
  
  Our Initiative and Impact
  
  Reports
  
  Our Sustainability Reports
  
  FY 2025
  
  FY 2024
  
  FY 2023
  
  More
  
  Our People
  
  The people who pave the way for a new world
  
  Equal Opportunity for all
  
  Employee Health and Safety
  
  Foundations
  
  Spearheading our social initiatives
  
  Glenmark Foundation
  
  Glenmark Aquatic Foundation
INVESTORS
- Investors
  
  INVESTORS
  
  Reports and Presentations
  
  Performance in numbers
  
  Shareholders Corner
  
  Be a part of the new world
  
  Latest Announcements
  
  For Investors and Shareholders
  
  ESG Profile
  
  Our Environment, Social & Governance initiatives
  
  Financial Results
  
  Growing from strength to strength
  
  Disclosures under Regulation 46
  
  Pursuant to SEBI LODR
  
  INVESTORS
  
  Latest Announcements
  
  For Investors and Shareholders
  
  Reports and Presentations
  
  Performance in numbers
  
  Financial Results
  
  Growing from strength to strength
  
  ESG Profile
  
  Our Environment, Social & Governance initiatives
  
  Shareholders Corner
  
  Be a part of the new world
  
  Disclosures under Regulation 46
  
  Pursuant to SEBI LODR
CAREERS
- Careers
  
  CAREERS
  
  Life at Glenmark
  
  Join Us
  
  CAUTION NOTICE REGARDING FRAUDULENT RECRUITMENT
  
  This is to notify to the public that certain unscrupulous persons, purporting to be part of and/or being authorised by the human resources department of Glenmark Pharmaceuticals Limited (“Glenmark”) are fraudulently offering jobs via certain websites/or through telephone calls, SMS or fake letters and asking the prospective job aspirants to appear for a face-to-face interview for a job opening with Glenmark and/or to pay a fee for securing a job with Glenmark. We wish to caution the public that Glenmark does not collect any monies or any other valuables as a pre or post-employment requirement.
  
  Click Here to Know More Click Here to Join Us
MEDIA
- Media
  
  MEDIA
  
  Newsroom
  
  Latest and archived press releases
  
  Library
  
  Resources and information
Toggle website search

ABOUT US
INNOVATION
- Overview
- R&D
- R&D Centres
- R&D Pipeline
RESPONSIBILITY
PRODUCTS
INVESTORS
CAREERS
- Life at Glenmark
- Join Us
MEDIA
- Newsroom
GLOBAL PRESENCE
- US
- India
- Europe
- Latin America
- Row
  - Asia
    - Malaysia
  - Africa
  - Russia & CIS

Newsroom

Home>
Media>
Newsroom

Media

Newsroom - 2026

Glenmark Pharmaceuticals Announces Q3 FY26 Results

30 Jan 2026 | READ MORE

Year – 2026
Year – 2025
Year – 2024
Year – 2023
Year – 2022
Year – 2021
Year – 2020
Year – 2019
Year – 2018
Year – 2017
Year – 2016
Year – 2015

ABOUT US
RESPONSIBILITY
PRODUCTS
INVESTORS
CAREERS
MEDIA
CONTACT US
TERMS AND CONDITIONS
REPORT A CONCERN
REPORT AN ADVERSE EVENT
PRIVACY PORTAL
INVESTIGATOR INITIATED TRIALS

© 2025 GLENMARK PHARMACEUTICALS LTD. ALL RIGHTS RESERVED